Skip to main content

Table 1 Demographic, metabolic and HIV characteristics of the patients

From: Soluble CD163 does not predict first-time myocardial infarction in patients infected with human immunodeficiency virus: a nested case–control study

Variable

Cases

Controls

p-valuea

Number of patients

55

182

 

Gender (male/female) (%)

50/5 (91/9)

167/15 (92/8)

 

Age at time of MI/index date median (IQR), years

49 (42 – 57)

50 (43 – 57)

 

Duration of HIV before MI/index date median (IQR), years

10 (6 – 17)

10 (7 – 16)

0.71

Mean duration of therapy before MI/index date median (IQR), years

6 (3 – 8)

6 (3 – 9)

 

Intervals between plasma samples

   

From sample 1 to initiation ART, median (IQR), days

42 (24 – 76)

49 (32 – 81)

 

From initiation of ART to sample 2 median (IQR), days

99 (88 – 123)

109 (87 – 142)

 

From sample 3 to MI/index date median (IQR), days

334 (292 – 367)

368 (334 – 408)

 

From sample 4 to MI/index date median (IQR), days

52 (27 – 82)

0 (0 – 0)

 

Smoking (never/ever) (%)

2/53 (4/96)

6/176 (3/97)

 

Blood pressure, systolic median (IQR)

135 (120 – 149) n = 36

125 (115 – 140) n = 87

0.09

CD4 cell count/mm3, median (IQR)¤

496 (290–688) n = 52

547 (307–800) n = 161

0.78

HIV-RNA copies/mL, median (range)¤

39 (19–217200)

39 (19–93900)

0.08

Number of patients with HIV-RNA < 400 copies/mL¤

44 (80%)

146 (89%)

0.12

Creatinine μM, median (IQR)¤

81 (70–89)

78 (70–88)

0.38

mg/dL, median (IQR)

1.1 (0.9–1.2) n = 48

1.0 (0.9–1.2) n = 148

 

Cholesterol mM, median (IQR)¤

6.3 (5.5–8.0)

5.7 (5.0–6.7)

0.38

mg/dL, median (IQR)

241 (214–309) n = 32

220 (193–255) n = 96

Lipid-lowering treatment (%)#

6

4

0.6

Starting antihypertensive treatment (%)#

13

4

0.07

Starting anti-coagulative treatment (%)#

4

3

0.67

Co-infected with hepatitis B (%) (HbsAg positive)

6

7

0.6

Co-infected with hepatitis C (%) (HCV-Ab-positive)

6

14

0.07

Exposed to ART (%)#

100

100

-

Exposed to NRTI (%)#

100

99.5

0.76

Exposed to abacavir (%)#

56

39

0.007

Exposed to NNRTI (%)#

73

58

0.006

Exposed to PI (%)#

87

84

0.24

  1. a univariate conditional logistic regression.
  2. ¤ plasma sample 4 (at time of MI/index date).
  3. # within the study period.
  4. Abbreviations: ART, Antiretroviral therapy; B-glucose, blood-glucose; HIV, Human immunodeficiency virus; MI, Myocardial infarction; NNRTI, Nonnucleoside reverse-transcriptase inhibitors; NRTI, Nucleoside reverse-transcriptase inhibitors; PI, Protease inhibitors.